



## Duke CFAR eNewsletter - November 2015

---

### Duke CFAR in the News

[\*The Plastic Pouch that Stops HIV\*](#)

**Robert Malkin**, professor of the Practice in Biomedical Engineering, head of the Developing World Healthcare Technologies Lab at Duke (DHT Lab) and Duke CFAR member

[\*Meningitis On The Move: Zebrafish Reveals Infection's Sci-Fi-Worthy Creep Into the Brain\*](#)

**David Tobin**, Assistant Professor of Molecular Genetics and Microbiology, and Duke CFAR member and Small Grant recipient

---

[Become a Duke CFAR Member](#)

---

### Core Spotlight

**CFAR Social and Behavioral Sciences (SBS) Core**

**Sweitzer selected for mentoring day at the 2015 CFAR SBSRN National Scientific Meeting**

The [Social and Behavioral Sciences Research Network \(SBSRN\)](#) is a collaborative network that links investigators from 21 CFARs. The SBSRN meets annually to foster cross CFAR collaborations between behavioral and social scientists. The 2015 meeting was hosted by Johns Hopkins University on October 29-30 in Baltimore. The theme of the meeting was “Integrating social, behavioral, and biomedical strategies: The future of HIV/AIDS prevention and care research.” Speakers and panels covered several important topics including behavioral challenges in biomedical prevention; structural intervention approaches to HIV prevention and improving HIV outcomes; the influence of gender on HIV acquisition and transmission, and NIH trends and priorities.

As part of the annual meeting activities, the SBSRN network holds a mentoring day to provide translational and early career investigators with the opportunity to engage with NIH representatives and senior SBSRN investigators regarding career development and grant writing. [Dr. Maggie Sweitzer](#), Assistant Professor in Psychiatry and Behavioral Sciences participated in the mentoring day. Dr. Sweitzer was mentored to develop a R21 proposal to evaluate the acceptability and preliminary efficacy of electronic cigarettes in reducing craving, withdrawal, and use of combustible cigarettes during a brief trial among HIV-infected smokers.

### **CFAR Administrative Core: Highlights from the 19th Annual National CFAR Meeting**

#### **Administrator's Meeting:**

*Announcement of a new co-funding institution- [National Institute on Minority Health and Health Disparities \(NIMHD\)](#)*

*Changes to the Progress Report*

- Shorter and simpler format
- Better coincides with the RPPR
- Directors' Overview has been condensed to 2 pages and should be an executive summary

#### **Director's Meeting:**

Focused on new NIH Funding Priorities. *See Announcements.*

How do the new NIH HIV/AIDS priorities affect the CFAR Program?

*NIH HIV Funded Research Base (FRB)*

- No immediate impact of guidelines on FY15 FRB
- New priorities will have an effect beginning in FY16 based on new guidelines
- CFAR eligibility and tier level will continue to be based on NIH-HIV/AIDS research

funding

#### *Local CFAR Vision*

- New NIH HIV/AIDS priorities underscore the message from the CFAR program over the years: focus on the most significant HIV/AIDS research questions and areas.
- Important to align the local CFAR vision with the highest overarching HIV/AIDS priority areas that promote and support the scientific expertise at the CFAR institution (s).

#### *CFAR Pilot Projects*

- Developmental Cores can target “RFAs” to NIH HIV/AIDS priority areas
- Ensure that applications submitted to the Core focus on HIV

#### *SWGs at CFARs*

- HIV-associated co-infections and co-morbidities
- Research towards a cure: cure/eradication/latency/reservoirs
- Reducing incidence: prevention
- HIV therapies: implementation research, continuum of care
- Crosscutting areas
- Basic research
- Health disparities
- Health and social issues linked with HIV
- High risk/special populations

#### *Going Forward*

- Co-funding of the CFAR program is not expected to be impacted
- CFARs should continue to support all NIH-funded HIV/AIDS research at their institution through the Cores
- CFARs should continue to advance the local HIV/AIDS research effort
- Continue to highlight high priority areas at the CFAR Directors’ meetings
- Supplements from NIH will continue to be geared towards priority areas, if funds are available

---

## Announcements



**The NIH has announced new HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding beginning fiscal year 2016.** ([NOT-OD-15-137](#)) The overarching NIH HIV/AIDS research priorities are: 1) research to reduce the incidence of HIV/AIDS, including the development of safe and effective HIV/AIDS vaccines; 2) development of the next generation of HIV therapies with improved safety and ease of use; 3) research towards a cure for HIV/AIDS; and 4) HIV-

associated comorbidities and co-infections. Basic research, health disparities, and training that cross-cut these priorities also will be supported.

The NIH has developed a series of guidelines for determining whether a research project has a high-, medium-, or low-priority for receiving AIDS-designated funding. These guidelines do not assess/determine the scientific and technical merit of a project only the priority for receiving AIDS-designated funds. A description of these priority topics and examples of each are provided below.

*High Priority topics of research for support using AIDS-designated funds*

- Reducing Incidence of HIV/AIDS
- Next generation of HIV therapies
- Research toward a cure
- Cross cutting areas: Basic research, health disparities, and training


*Medium Priority topics of research for support using AIDS-designated funds* include projects that demonstrate HIV/AIDS is a meaningful component of the project and/or knowledge about HIV will be enhanced by the project, as evidenced in the specific aims.

*Low Priority topics of research* will not be supported with AIDS-designated funds; however, highly meritorious projects could be eligible for support with non-AIDS funds by an NIH Institute or Center.



**The DART CFAR CAB** had a display table at the Center for Information and Study on Clinical Research Participation (CISCRP) Aware for All event held at the Friday Center on Oct. 22nd, 2015. Over 200 participants attended the event. Three members of the DART CFAR CAB, Rita McDaniel, Julia Giner, and Teri Gleason displayed HIV, Sexually Transmitted Infection, and Hepatitis C information during the health screening event preceding the professional and participant panel discussions.



 **The National CFAR CAB coalition** meeting was held on Nov. 4, 2015 in Seattle, Washington, and was attended by Duke CFAR CAB representative, Michael Stewart. There were two main milestones accomplished by the CAB during the meeting. The first was the review and acceptance of the by-laws by all National CAB representatives present. The second was the election of National CFAR CAB representative roles, including: Chair, Vice-Chair, Secretary, and Treasurer.

Day 2 of the conference was the CFAR Scientific Symposium with presentations in many areas of HIV research. Members of the National CFAR CAB coalition attended and asked questions and provided community feedback.

## Upcoming Events

### [World AIDS Day](#)

Tuesday, December 1, 2015

### [Duke-UNC Symposium on Viral Oncology and AIDS Malignancy](#)

Wednesday, December 2, 2015

Great Hall, Trent Semans Center

### [UNC 17th Annual World AIDS Day Symposium](#)

Friday, December 4, 2015  
 8:30am-3:10pm  
 Bioinformatics Building 1131, UNC Campus

[Winter Walk for AIDS - Triad Health Project](#)  
 Sunday, December 6, 2015  
 UNC Greensboro

[Duke AIDS Research and Treatment Center \(DART\) CFAR Community Advisory Board \(CAB\) Annual Forum](#)  
 Monday, December 7, 2015  
 Room 040 Trent Hall

#### All Upcoming Events

---

## Publications citing Duke CFAR

*\*Please remember to cite the Duke CFAR: P30 AI064518\**

**New** [Would you test for 5000 Shillings? HIV risk and willingness to accept HIV testing in Tanzania.](#)

Ostermann J, Brown DS, Mühlbacher A, Njau B, Thielman N.  
 Health Econ Rev. 2015 Dec;5(1):60. doi: 10.1186/s13561-015-0060-8. Epub 2015 Aug 19.  
 PMID: 26285777

[Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.](#)

Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, Yang Y, Parks R, Archin N, Allard B, Kirchherr J, Kuruc JD, Gay CL, Cohen MS, Ochsenbauer C, Soderberg K, Liao HX, Montefiori D, Moore P, Johnson S, Koenig S, Haynes BF, Nordstrom JL, Margolis DM, Ferrari G.  
 J Clin Invest. 2015 Nov 2;125(11):4077-90. doi: 10.1172/JCI82314. Epub 2015 Sep 28.  
 PMID: 26413868

**New** [Vaginal Self-Sampling for Human Papillomavirus Infection as a Primary Cervical Cancer Screening Tool in a Haitian Population.](#)

Boggan JC, Walmer DK, Henderson G, Chakhtoura N, McCarthy SH, Beauvais HJ, Smith JS.

Sex Transm Dis. 2015 Nov;42(11):655-9. doi: 10.1097/OLQ.0000000000000345. PMID: 26462192

[Establishment of biochemistry reference values for healthy Tanzanian infants, children and adolescents in Kilimanjaro Region.](#)

Buchanan AM, Fiorillo SP, Omondi MW, Cunningham CK, Crump JA.

Trop Med Int Health. 2015 Nov;20(11):1569-1577. doi: 10.1111/tmi.12580. Epub 2015 Aug 25.

PMID: 26224122

**New** [Characterizing the Switching Thresholds of Magnetophoretic Transistors.](#)

Abedini-Nassab R, Joh DY, Van Heest MA, Yi JS, Baker C, Taherifard Z, Margolis DM, Garcia JV, Chilkoti A, Murdoch DM, Yellen BB.

Adv Mater. 2015 Oct;27(40):6176-80. doi: 10.1002/adma.201502352. Epub 2015 Sep 9.

PMID: 26349853

**New** [Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.](#)

Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH.

Cancer Immunol Immunother. 2015 Oct;64(10):1271-86. doi: 10.1007/s00262-015-1729-x. Epub 2015 Jun 28.

PMID: 26122357

**New** [HIV/AIDS-related stigma in South African alcohol-serving venues and its potential impact on HIV disclosure, testing and treatment-seeking behaviours.](#)

Velloza J, Watt MH, Choi KW, Abler L, Kalichman SC, Skinner D, Pieterse D, Sikkema KJ.

Glob Public Health. 2015 Oct;10(9):1092-106. doi: 10.1080/17441692.2014.1001767.

Epub 2015 Jan 29.

PMID: 25630531

**New** [Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1.](#)

Pollara J, McGuire E, Fouda GG, Rountree W, Eudailey J, Overman RG, Seaton KE, Deal A, Edwards RW, Tegha G, Kamwendo D, Kumwenda J, Nelson JA, Liao HX, Brinkley C, Denny TN, Ochsenbauer C, Ellington S, King CC, Jamieson DJ, van der Horst C, Kourtis AP, Tomaras GD, Ferrari G, Permar SR.

J Virol. 2015 Oct;89(19):9952-61. doi: 10.1128/JVI.01560-15. Epub 2015 Jul 22.

PMID: 26202232

[Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.](#)

Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, Vandergrift NA, Alam SM, Ferrari G, Shen X, Tomaras GD, Kamanga G, Cohen MS, Sam NE, Kapiga S, Gray ES, Tumba NL, Morris L, Zolla-Pazner S, Gorny MK, Mascola JR, Hahn BH, Shaw GM, Sodroski JG, Liao HX, Montefiori DC, Hraber PT, Korber BT, Haynes BF.  
Cell Host Microbe. 2015 Sep 9;18(3):354-62. doi: 10.1016/j.chom.2015.08.006.  
PMID: 26355218

**New** [Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.](#)

Amos JD, Himes JE, Armand L, Gurley TC, Martinez DR, Colvin L, Beck K, Overman RG, Liao HX, Moody MA, Permar SR.  
J Virol. 2015 Sep;89(18):9485-98. doi: 10.1128/JVI.01564-15. Epub 2015 Jul 8.  
PMID: 26157116

**New** [Expression of CRISPR/Cas single guide RNAs using small tRNA promoters.](#)

Mefferd AL, Kornepati AV, Bogerd HP, Kennedy EM, Cullen BR.  
RNA. 2015 Sep;21(9):1683-9. doi: 10.1261/rna.051631.115. Epub 2015 Jul 17.  
PMID: 26187160

**New** [Mental Health and Substance Use Among Patients in a North Carolina HIV Clinic.](#)

Skalski LM, Watt MH, MacFarlane JC, Proeschold-Bell RJ, Stout JE, Sikkema KJ.  
N C Med J. 2015 Jul-Aug;76(3):148-55. doi: 10.18043/ncm.76.3.148.  
PMID:26510216

Full List of Duke CFAR Publications

---

## Funding Opportunities

**Deadline extended**

**The Creative and Novel Ideas in HIV Research (CNIHR)** grant program has extended the deadline for Concept Proposals for its [latest round of funding](#) to December 11, 2015.

**New** [UCLA mSTUDY Databank - Request for Proposals](#)



**New** [UCSF CAPS Visiting Professors Program](#)**New** **Gilead Sciences Research Scholars Program in HIV**<http://researchscholars.gilead.com>

Application Receipt/Submission Date: Midnight EST December 11, 2015

**New** **HIV/AIDS Vaccine Scholars Program (K01)** [\(PAR-16-028\)](#)

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Application Receipt/Submission Date(s): January 11, 2016; January 11, 2017 and January 11, 2018, by 5:00 PM local time of applicant organization.

**New** **Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01)**[\(RFA-DK-16-014\)](#)

National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt Date(s): March 09, 2016

**New** **Innovative Research in HIV in Kidney, Urology, and Hematology (R01)**[\(RFA-DK-16-015\)](#)

National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt Date(s): March 09, 2016

**New** **Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01)**[\(RFA-DK-16-016\)](#)

National Institute of Diabetes and Digestive and Kidney Diseases

Application Receipt Date(s): March 09, 2016

**Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21)**

Application Receipt Date(s): Jan 11, 2016, 2017, 2018

<http://grants.nih.gov/grants/guide/pa-files/PAR-15-360.html>**Scientific/Research Contact(s)**

Cesar Boggiano, PhD

Division of AIDS,

National Institute of Allergy and Infectious Diseases (NIAID)

Telephone: 240-627-3038

Email: [cesar.boggiano@nih.gov](mailto:cesar.boggiano@nih.gov)

Katrin Eichelberg, PhD

Division of Microbiology and Infectious Diseases,

National Institute of Allergy and Infectious Diseases (NIAID)

Telephone: 240-669-2921

Email: [keichelberg@niaid.nih.gov](mailto:keichelberg@niaid.nih.gov)

Alison Deckhut Augustine, PhD

Division of Allergy, Immunology and Transplantation,

National Institute of Allergy and Infectious Diseases (NIAID)

Telephone: 240-627-3475

Email: [augustine@niaid.nih.gov](mailto:augustine@niaid.nih.gov)

## All Current Funding

If you have content for the Duke CFAR eNewsletter, please send it by the first of the month to [kelly.plonk@duke.edu](mailto:kelly.plonk@duke.edu) to have it published in the next eNewsletter.

---



---

*Copyright © 2015 Duke CFAR, All rights reserved.*

**Our mailing address is:**

Duke CFAR  
915 S. LaSalle Street  
DUMC Box 2926  
Durham, Nc 27710

[Add us to your address book](#)

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#)

The MailChimp logo, featuring the word "MailChimp" in a white, cursive font on a grey rectangular background.